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Exploiting the dependence of cancer cells on transcription can be used as an effective strategy for
targeting aggressive and therapeutically recalcitrant tumors. Wang et al. show that inhibiting tran-
scription using THZ1, a small-molecule inhibitor of cyclin-dependent kinase CDK7, induces
apoptotic cell death in triple-negative breast cancers.Large-scale, deep-sequencing-based
genomic analyses have revealed a sur-
prising level of genetic heterogeneity in
cancers. In some cancers, ‘‘driver’’ muta-
tions in key oncogenes can be parsed out
from the background of genetic heteroge-
neity. Some of these oncogenes (such as
BRAF and EGFR) encode mutant proteins
that provide opportunities for rational tar-
geting by drugs (for instance, targeting
BRAF V600E by Vemurafenib and Dabra-
fenib inmelanoma; targeting EGFR L858R
or exon 19 deletions by Afatinib and Gefi-
tinib in non-small-cell lung cancer) (Bollag
et al., 2012; Sordella et al., 2004). For
other cancers, such as triple-negative
breast cancer (TNBC), definitive driver
mutations have not been identified and
thus lack targeted therapies. In spite of
a high level of genetic heterogeneity,
TNBCs maintain a characteristic and
readily identifiable pattern of gene
expression. In this issue of Cell, Wang
et al. (2015) hypothesize that mainte-
nance of a uniform gene expression pro-
gram in TNBCs requires continually active
transcription, which might make these
cancers highly sensitive to drugs that
inhibit transcription (Figure 1A).
Recent studies using small-molecule
inhibitors of the transcriptional machinery
have shown promising selectivity for
cancer cells and potent antiproliferative
effects. For example, targeting bromodo-
main and extra-terminal proteins (BET)
family members, such as BRD4, with
JQ1 has exploited the dependence of
certain cancers on the transcription of
critical driver oncogenes (e.g., c-Myc),
rendering these cancers sensitive to tran-28 Cell 163, September 24, 2015 ª2015 Elsescriptional inhibition (Delmore et al.,
2011). More recently, THZ1, a selective
covalent inhibitor of cyclin-dependent
kinase CDK7, has been shown to be
effective in inhibiting the growth of several
cancers, such as T cell acute lympho-
blastic leukemia (Kwiatkowski et al.,
2014), MYCN-amplified neuroblastoma
(Chipumuro et al., 2014), and small-cell
lung cancer (Christensen et al., 2014).
Wang et al. (2015) explore the thera-
peutic potential of targeting CDK7 in
TNBC, a therapeutically recalcitrant sub-
type of breast cancer that does not ex-
press estrogen receptors (ERs, the target
of the first-line therapeutic Tamoxifen),
progestin receptors (PRs), or theHER2 re-
ceptor (ERBB2; a receptor tyrosine-pro-
tein kinase). Using THZ1 and CRISPR/
Cas9-mediated gene editing, the authors
observe that TNBC cells, but not ER-pos-
itive/PR-positive breast cancer cells, are
highly dependent on the transcriptional
functions of CDK7. Inhibition of CDK7
with THZ1 promotes apoptotic cell death
in both TNBC cell lines and patient-
derived tumor samples.
CDK7 is a cyclin-dependent kinase
(CDK) and a subunit of the multi-protein
basal transcription factor TFIIH. As such,
it plays dual roles in the regulation of
cell-cycle progression and transcription.
As a component of the CDK Activating Ki-
nase (CAK), CDK7 is involved in control of
the cell cycle by phosphorylating other
cell-cycle CDKs, such as CDK1 and
CDK2 (Malumbres, 2014). As a compo-
nent of TFIIH, CDK7 regulates transcrip-
tion initiation by phosphorylating serines
5 and 7 of the heptapeptide repeat in thevier Inc.C-terminal domain (CTD) of the largest
subunit (RPB1) of RNA polymerase II
(Pol II) (Malumbres, 2014) (Figure 1B). In
their study, Wang et al. (2015) demon-
strate that THZ1-mediated inhibition of
CDK7 does not alter the cell cycle in
TNBC cells, suggesting that the sensitivity
of TNBCs to THZ1 is mediated through
transcriptional inhibition.
Following from their initial observations,
the authors postulate that TNBCs are
dependent on the uninterrupted tran-
scription of a key set of genes whose
expression supports the cancer pheno-
type. Indeed, they identified a set of
450 genes whose expression is highly
sensitive to inhibition of CDK7 by THZ1,
which they refer to as an ‘‘Achilles cluster’’
of TNBC-specific genes (Figure 1A). Gene
ontology analyses revealed that this gene
set is enriched for factors involved in
signaling and transcription regulation,
including genes encoding signaling mole-
cules and transcription factors with estab-
lished roles in breast cancer (e.g., TGFB,
STAT, and WNT). Interestingly, these
genes are associated with large clustered
enhancer regions (so-called ‘‘super en-
hancers’’), which are required to drive
high-level expression of these genes.
The authors posit that targeting CDK7-
dependent transcription is an effective
way to collectively suppress the expres-
sion of multiple genes that are critical for
the proliferation of TNBC cells. As such,
this gene set may have utility as a prog-
nostic signature for tumors that can be
treated effectively with THZ1.
Recent studies have suggested that
cancer cells have a higher overall
Figure 1. Inhibition of CDK7 by THZ1 and Its Therapeutic Implications
(A) Cancer cells are characterized by increased genomic heterogeneity compared to normal cells. In some
cancers, driver mutations in key oncogenes can be targeted therapeutically to inhibit cancer cell growth or
induce apoptosis. In cancers with no clear driver mutations, such as TNBC, inhibitors such as THZ1 can be
used to target ‘‘transcription addiction’’ to a set of ‘‘Achilles cluster’’ genes that encode for factors involved
in signaling and transcription regulation. Many cancer cells can be killed with DNA-damaging agents,
which wreak havoc on the genome.
(B) THZ1 covalently binds to and inhibits the activity of CDK7 (a subunit of TFIIH), preventing phosphor-
ylation of the C-terminal domain (CTD) of the largest subunit (RPB1) of RNA polymerase II (Pol II) and
inhibiting productive transcription initiation.
(C) Current models posit that tumor cells have a higher overall transcription output than normal cells,
allowing for more opportunities to engage oncogenic pathways. General inhibition of transcription can
have a therapeutic benefit by decreasing the overall transcription output to levels similar to those observed
normal cells.
(D) Due to the universal role and biological importance of transcription in all cells, the therapeutic window
between efficacy and toxicity for malignant and non-malignant cells will determine if THZ1 can be used to
treat human patients.transcriptional output than non-malignant
cells (Lin et al., 2012). This may increase
the likelihood of these cancer cells
to engage in oncogenic pathways
(Figure 1C). Inhibition of transcription
may, therefore, reduce the transcriptional
output of cancer cells to levels that are
less likely to feed into oncogenic path-
ways (Figure 1C). However, due to the
universal role and biological importance
of transcription in all cells, targeting tran-
scription as a therapeutic strategy may
be challenging due to the potential lack
of selectivity for cancer cells over normalcells. Therefore, it is imperative to deter-
mine if the therapeutic window between
efficacy and toxicity for malignant and
non-malignant cells is large enough to
produce a therapeutically efficacious ef-
fect (Figure 1D).
This situation is analogous, in some
respects, to the use of DNA-damaging
therapeutics. All cells need to maintain a
certain level of genome integrity to sur-
vive, but highly proliferative cells, such
as cancer cells, are more sensitive the
effects of DNA-damaging drugs. In fact,
this is the basis of synthetic lethality withCell 163, SPARP inhibitors in BRCA1/2-depleted
cancers. While current chemotherapeutic
agents used to induce DNA damage
exploit the requirement for cancer cells
to frequently replicate their genomes, a
similar dependence on transcription can
now be exploited with transcription inhib-
itors, such as THZ1.
In spite of recent advances in genomic
sequencing, clear driver mutations have
yet to be discovered for TNBCs. While
ER-positive/PR-positive breast cancers
are effectively treated with hormone ther-
apies, the more aggressive TNBCs lack
targeted therapies, and cytotoxic chemo-
therapy remains the standard treatment
(Mayer et al., 2014). Thus, THZ1 and its
derivatives are promising candidates for
the treatment of TNBCs. Wang et al.
(2015) have developed an analog of
THZ1 (THZ2) with improved pharmacoki-
netics that has few side effects in mouse
xenograft models, which may be more
useful clinically. The growth-promoting
pathways that are activated in cancer
cells involve multiple redundancies.
Therefore, the use of a targeted therapeu-
tic agent that selectively inhibits one
pathway may be undermined by the
activation of a compensatory pathway
(Mayer et al., 2014). The strategy of tar-
geting transcription more generally may
be effective in these cases. Moreover,
combining targeted agents with transcrip-
tional inhibitors may be an effective
approach for the treatment of TNBC,
which may minimize therapeutic resis-
tance of these difficult-to-treat cancers.
If THZ1-based therapy can be effectively
translated into the clinic, the identification
of biomarkers, perhaps an enhancer
signature, that can predict if a given tumor
will be sensitive to CDK7 inhibition will be
essential.
In sum, this study highlights the enor-
mous potential for targeting transcrip-
tional addiction in aggressive tumors.
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Retroviral restriction is a complex phenomenon that, despite remarkable recent progress, is far
from being well understood. In this Preview, we introduce an insightful study by Yang et al. that
represents the first attempt to identify the global determinants of retroviral repression in pluripotent
mammalian cells.To protect their genomic integrity, animals
control retroviral infections by establish-
ing heritable epigenetic silencing of the
integrated provirus in early embryonic
development. In mouse embryonic stem
cells (ESCs), KAP1 (Trim28) is targeted
to newly integrated Moloney murine leu-
kemia virus (MMLV) by the Krueppel-
associated box (KRAB) zinc finger protein
ZFP809. KAP1, in turn, recruits histone-
modifying enzymes, including the histone
methyl transferase SETDB1 (ESET), that
deposit repressive histone 3 lysine 9
trimethylation (H3K9me3) marks at the
provirus (Figure 1) (Matsui et al., 2010;
Rowe et al., 2010; Wolf and Goff, 2009).
The KRAB/KAP1 system also represses
endogenous retroviruses (ERVs), which
are potentially hazardous remnants of
retroviral germline infections (Matsui
et al., 2010; Rowe et al., 2010; Wolf
et al., 2015). Additionally, several cofac-
tors of the KRAB/KAP1 system, but also
KAP1-independent retroviral repression
pathways, have been identified over the
last few years. Indeed, the abundance
and sequence diversity of exogenous
and endogenous retroviruses likely droveevolution of complex and partially redun-
dant repression mechanisms that keep
these elements under control. Moreover,
some ERVs have been adapted as
new regulatory elements and, in some
cases, have re-wired entire transcriptional
networks (Macfarlan et al., 2012). Retro-
viral repression mechanisms might
therefore also regulate transcription of
cellular genes. Despite recent progress
in the field, deciphering the complexity
and interconnectivity of retroviral repres-
sion pathways and networks remains
an outstanding problem of mammalian
genome biology. The Resource article
by Yang et al. (2015) performs a
genome-wide small interfering RNA
(siRNA) knockdown screen in a first
attempt to determine in a global manner
the components of retroviral repression
machinery in mammalian pluripotent
cells.
The siRNA screen was performed using
a MMLV reporter that is repressed by
ZFP809/KAP1 and is therefore primarily
aimed at identifying cofactors acting up-
and downstream of the KRAB/KAP1 sys-
tem, but also at potentially overlappingKAP1-independent repression pathways.
Apart from previously known factors,
including ZFP809, KAP1, and SETDB1,
hundreds of new repression candidates
were identified. As expected,many candi-
dates are associated with chromatin
modification, DNA methylation, and regu-
lation of transcription. Additionally, the
screen identified genes involved in protein
sumoylation, DNA repair, and DNA repli-
cation and even factors located outside
of the nucleus (e.g., plasma membrane,
cytoskeletal, and organelle proteins).
These findings highlight the complexity
of retroviral restriction networks in
mammalian cells, although many of these
factors may not primarily, specifically,
and/or directly repress retroviruses.
Without a doubt, the provided candidate
list is a potentially valuable resource for
future studies that may address how
these factors mediate retroviral restriction
and ultimately help us to better under-
stand how epigenetic silencing of retro-
viruses is established, maintained, and
inherited during development.
Two of the newly identified repression
mechanisms are subsequently analyzed
